Benefits
NASH 6-month RCT 28-pt (PMID 32657670)
Chiou YL et al. 2020 PMID 32657670 — first clinical investigation of A. cinnamomea mycelium (ACM) hepatoprotective effect in NONALCOHOLIC STEATOHEPATITIS. 28 patients randomized double-blind placebo-controlled to 3 capsules/day (420 mg ACM) or 420 mg starch placebo × 6 months. Hospital visits every 3 months for anthropometric + biochemical + immune assessment. NO adverse events — ACM safe alternative for NASH.
Subhealth ALT 12-week RCT 44-pt (PMID 36476310)
PMID 36476310 — randomized double-blind placebo-controlled clinical study in subhealth Japanese adults (ALT 31-50 U/L, AST ≤50 U/L). 44 enrolled. ACME capsule (250 mg ACME powder) or placebo daily × 12 weeks. Primary outcomes ALT + AST analyzed at 0, 4, 8, 12 weeks. NO treatment-related adverse effects observed throughout.
Antroquinonol Nrf-2 hepatoprotection (PMID 21540101)
Kumar KJ et al. 2011 PMID 21540101 (J Ethnopharmacol 136:168-177, doi:10.1016/j.jep.2011.04.030) — antroquinonol from ethanolic extract of A. cinnamomea mycelium (EMAC) protects hepatic cells from ethanol-induced oxidative stress through NRF-2 ACTIVATION. HepG2 cells + ICR mice models. Foundational hepatoprotective mechanism.
Antrodan glycoprotein hepatoprotection (PMC3972158)
Ker YB et al. 2014 (PLoS ONE 9:e93191, doi:10.1371/journal.pone.0093191) — ANTRODAN protein-bound polysaccharide from A. cinnamomea mycelia exhibits significant ANTI-INFLAMMATORY bioactivity in vitro. In vivo hepatic injury model — beneficial hepatoprotective effects. Foundational glycoprotein mechanism.
Hepatoprotective review evidence (PMC3819176)
Yue PY et al. 2013 PMC3819176 (doi:10.1186/1749-8546-8-21) — review of A. cinnamomea hepatoprotective activities. Diverse pharmacological activities: anti-hypertension, anti-hyperlipidemia, anti-inflammation, anti-oxidation, anti-tumor, immunomodulation. Evidence for HEPATIC PROTECTION is most recognized + strongest. Inhibits hepatic tumor growth + retards hepatitis progression.
Alcohol-induced liver injury mouse model (PMC5350382)
Liu Y et al. 2017 PMC5350382 (doi:10.1155/2017/7841823) — A. cinnamomea mycelia hepatoprotective effects in mouse model of acute alcohol-induced liver injury. AC contained 25 fatty acids + 16 amino acids + 3 nucleotides + 8 minerals. Modulation of OXIDATIVE STRESS SIGNALING. Foundational mechanism evidence.
HONEST limited human RCT evidence + FDA non-approval
HONEST framing per PMC3819176: 'human and clinical trials are still LIMITED, and further studies are required for the development of AC-related products'. FDA has NOT approved any AC extracts or purified compounds for clinical applications. Currently used as FOOD SUPPLEMENT only. Taiwan-endemic species — limited cultivation outside Taiwan.
Mechanism of action
Antroquinonol Nrf-2 antioxidant pathway
Antroquinonol from EMAC activates NRF-2 → antioxidant response element → hepatocyte protection from ethanol-induced oxidative stress (Kumar 2011 PMID 21540101). Distinguishing hepatoprotective mechanism.
Antrodan protein-bound polysaccharide anti-inflammatory
Antrodan glycoprotein from mycelia exhibits anti-inflammatory bioactivity. Mechanism: protein-polysaccharide complex modulating inflammatory pathways. Foundational glycoprotein hepatoprotection (Ker 2014).
Hepatic tumor growth inhibition
AC inhibits hepatic tumor growth + retards hepatitis progression (Yue 2013 review). Mechanism: multi-pathway anti-tumor activity in hepatic context. Foundational anti-hepatocarcinoma evidence.
Anti-hyperlipidemia + anti-hypertension
Diverse pharmacological activities including anti-hyperlipidemia + anti-hypertension. Mechanism: cardiometabolic effects supporting broader liver-cardio axis. Foundational systemic mechanism.
Multi-component oxidative stress modulation
Liu 2017 PMC5350382 — AC mycelia contains 25 fatty acids + 16 amino acids + 3 nucleotides + 8 minerals. Modulation of oxidative stress signaling in alcohol-induced liver injury. Multi-component mechanism.
Immunomodulation activity
AC modulates immune function — anti-inflammation + immune cell modulation. Mechanism: contributes to integrative therapeutic profile beyond direct hepatoprotection.
Clinical trials
Randomized double-blind placebo-controlled trial (Chiou YL, Chyau CC, Li TJ, Kuo CF, Kang YY, Chen CC, Ko WS 2020).
28 NASH patients. 3 capsules/day = 420 mg ACM (Antrodia cinnamomea mycelium) OR 420 mg starch placebo × 6 months. Hospital visits every 3 months for anthropometric + biochemical + immune function assessment.
FIRST clinical investigation exploring hepatoprotective effect of ACM in NASH patients. NO adverse events during study — ACM SAFE alternative treatment for NASH. Foundational human evidence in non-alcoholic steatohepatitis adjunct context.
Randomized double-blind placebo-controlled clinical study.
44 Japanese adults with subhealth ALT levels (31-50 U/L) + AST ≤50 U/L. ACME capsule (250 mg ACME powder) OR placebo daily × 12 weeks. Primary outcomes ALT + AST at 0, 4, 8, 12 weeks.
First study assessing ameliorating effect of ACME on liver health in asymptomatic individuals with marginally high ALT levels. NO treatment-related adverse effects observed. Foundational subhealth liver function evidence — preventive context vs disease state.
Review article (Yue PY et al. 2013, doi:10.1186/1749-8546-8-21).
Synthesis of A. cinnamomea hepatoprotective research — in vitro + in vivo + clinical preliminary studies.
AC pharmacological activities: anti-hypertension, anti-hyperlipidemia, anti-inflammation, anti-oxidation, anti-tumor, immunomodulation. EVIDENCE FOR HEPATIC PROTECTION most recognized + strongest. Inhibits hepatic tumor growth + retards hepatitis progression. HONEST: human clinical trials still LIMITED; further studies required for AC product development. FDA has NOT approved AC products for clinical applications.
About this ingredient
ANTRODIA CINNAMOMEA (also known as ANTRODIA CAMPHORATA) is a MEDICINAL MUSHROOM ENDEMIC TO TAIWAN — Chinese name 'NIU-CHANG-CHIH'. Polyporaceae family. First identified as new species by Zang and Su 1990. Among its diverse pharmacological activities, evidence for HEPATIC PROTECTION is the most recognized + strongest. Active compounds: ANTROQUINONOL, ANTRODAN (protein-bound polysaccharide glycoprotein), TRITERPENOIDS, POLYSACCHARIDES, fatty acids, amino acids, nucleotides, minerals. PIVOTAL CLINICAL EVIDENCE: CHIOU YL et al. 2020 PMID 32657670 — FIRST clinical investigation of ACM hepatoprotective effect in NASH. 28 patients randomized double-blind placebo-controlled to 3 capsules/day (420 mg ACM) or 420 mg starch placebo × 6 months. NO adverse events — ACM safe alternative for NASH. PMID 36476310 — randomized double-blind placebo-controlled study in 44 SUBHEALTH JAPANESE adults (ALT 31-50 U/L, AST ≤50 U/L). 250 mg ACME × 12 weeks. NO treatment-related AEs. KUMAR KJ et al. 2011 PMID 21540101 (J Ethnopharmacol 136:168-177, doi:10.1016/j.jep.2011.04.030) — ANTROQUINONOL from EMAC protects hepatic cells from ethanol-induced oxidative stress through NRF-2 ACTIVATION (HepG2 + ICR mice). KER YB et al. 2014 PMC3972158 (PLoS ONE 9:e93191, doi:10.1371/journal.pone.0093191) — ANTRODAN protein-bound polysaccharide from mycelia exhibits anti-inflammatory bioactivity. YUE PY et al. 2013 PMC3819176 (doi:10.1186/1749-8546-8-21) hepatoprotective review. LIU Y et al. 2017 PMC5350382 (doi:10.1155/2017/7841823) alcohol-induced liver injury mouse model — oxidative stress signaling modulation.
MECHANISMS: ANTROQUINONOL Nrf-2 antioxidant pathway (hepatocyte protection from ethanol-induced oxidative stress); ANTRODAN protein-bound polysaccharide anti-inflammatory (glycoprotein modulation); HEPATIC TUMOR growth inhibition + hepatitis progression retardation; ANTI-HYPERLIPIDEMIA + anti-hypertension activities; MULTI-COMPONENT oxidative stress modulation; IMMUNOMODULATION activity. EVIDENCE: 3/5 reflects: (1) CHIOU 2020 PMID 32657670 6-month NASH RCT (n=28), (2) PMID 36476310 12-week subhealth ALT RCT (n=44 Japanese), (3) KUMAR 2011 antroquinonol Nrf-2 mechanism evidence, (4) KER 2014 antrodan glycoprotein mechanism, (5) YUE 2013 hepatoprotective comprehensive review, (6) LIU 2017 alcohol-induced liver injury mouse model, (7) TAIWAN-ENDEMIC species — distinguishing geographic specificity, (8) TRADITIONAL Niu-Chang-Chih medicinal use record, (9) HONEST CRITICAL LIMITATION — human clinical trials still LIMITED, FDA has NOT approved AC products for clinical applications, (10) higher-evidence than typical hepatoprotective mushroom due to dedicated NASH + subhealth ALT RCTs. SAFETY: Excellent — 6-month NASH RCT + 12-week subhealth ALT RCT both reported NO adverse events. Best positioned as: (a) NASH ADJUNCT (Chiou 2020 6-month evidence), (b) SUBHEALTH LIVER FUNCTION support (PMID 36476310 ALT/AST evidence), (c) ALCOHOL-INDUCED LIVER PROTECTION (Kumar 2011 antroquinonol mechanism + Liu 2017 mouse model), (d) HEPATITIS adjunct context (Yue 2013 review evidence), (e) INTEGRATIVE LIVER HEALTH support, (f) MULTI-MECHANISM hepatoprotection (Nrf-2 + antrodan glycoprotein + multi-component), (g) TAIWAN-SOURCED supplement context (endemic species), (h) PREGNANCY: limited specific data, (i) FDA NON-APPROVAL: supplement only, not clinical application, (j) higher-evidence than mainstream 'liver mushroom' supplements due to dedicated NASH RCT. Honest framing: Antrodia cinnamomea has SOLID EMERGING EVIDENCE for hepatoprotective applications — Chiou 2020 NASH RCT + PMID 36476310 subhealth ALT RCT + Kumar 2011 antroquinonol Nrf-2 mechanism + Ker 2014 antrodan mechanism establish clinical + biochemical foundation. CRITICAL HONEST LIMITATIONS per PMC3819176: 'human and clinical trials are still LIMITED, further studies are required for AC product development'. FDA has NOT approved any AC products for clinical applications — supplement only context. Taiwan-endemic species limits cultivation outside Taiwan + distinguishes from globally cultivated medicinal mushrooms. Antroquinonol + antrodan are biochemically distinguishing among medicinal mushroom hepatoprotective compounds. Reasonable hepatoprotective adjunct for NASH + subhealth ALT + alcohol exposure based on dedicated RCT evidence — particularly compelling for those wanting Taiwan-traditional liver support with documented mechanisms (Nrf-2, antrodan glycoprotein). Position as EMERGING evidence base — preliminary RCTs supportive but additional rigorous trials still needed.